VentureBeat

TODAY’S HEADLINES:

• Breathe Tech raises $15M for respiratory disease (release)
• Protein-drug maker Pieris takes in €25M (release)
• Apthera takes in $2.1M toward cancer vaccine (VentureWire)

Breathe Tech raises $15M for respiratory disease – Breathe Technologies, a Fremont, Calif., medical device maker, raised $15 million in a second round of funding. Investors included Kleiner Perkins Caufield & Byers, Synergy Partners International, Delphi Ventures and Life Science Angels.

Breathe is developing “compact” and “lightweight” respiratory systems for the hospital and home markets, and estimates that annual sales of the devices its equipment could enhance or replace amount to $2 billion. The Breathe ventilators could be used by patients with chronic obstructive pulmonary disease, cystic fibrosis, and other lung disorders.

Protein-drug maker Pieris takes in €25M – Pieris, a German biotech pursuing a new form of protein-based drug, raised €25 million ($38 million) in a second funding round. Investors included OrbiMed Advisors, Novo Nordisk, Global Life Science Ventures, Gilde Healthcare Partners and Forbion Capital Partners.

Pieris is the latest biotech to think it can improve on monoclonal antibodies as drug candidates by developing its own engineered protein structures. The startup calls its protein structures Anticalins — they’re derived from a class of human proteins called lipocalins — and says they’re smaller and simpler than monoclonals with similar power to selectively bind to particular molecular targets.

Pieris joins a number of other companies pursuing similar strategies, including Adnexus Therapeutics, which sold itself to Bristol-Myers Squibb for $430 million, and Molecular Partners, a Swiss biotech working on modular proteins it calls DARPins. Although these are all interesting ideas, none have yet proven themselves, and all have to address a potentially significant hurdle — the fact that none of these engineered proteins are likely to engage the immune system’s disease-fighting elements the way monoclonal antibodies often do.

Apthera takes in $2.1M toward cancer vaccine – Apthera, a Scottsdale, Ariz., biotech working on therapeutic cancer vaccines, raised $2.1 million of an expected $3.9 million second funding round, VentureWire reports. Investors included the University of Texas M.D. Anderson Cancer Center, Blackmont Capital, Land Ventures and individuals.

Apthera is developing a vaccine intended to stimulate an immune response against breast-cancer cells. The startup plans to start a late-stage, phase III trial of the vaccine in the fourth quarter of this year, and hopes to raise another $10 million later this year to finance the test.

TODAY’S HEADLINES:

• Teva acquires protein-therapeutic maker CoGenesys for $400M (release)
• ViewRay takes in $25M for MRI radiation-therapy guidance (release)
• NovaMed, Chinese clinical-research outfit, receives $14M (release)
• Progentix Ortho raises first funding round (release)
• Medical imaging co. Point Biomedical recaps with $25M (VentureWire)
• Lumidigm takes in $7M for optical-fingerprint ID systems (VW)
• Medical-software co. Compressus aims to close $14M round (VW)
• Channel Medical Partners aims for $150M med-tech fund (VW)
• Spinal-implant maker Scient’x names Michael Huggins as CEO (release)
• Specialty pharma Cardiokine names Manuel Worcel as CEO (release)
• Respiratory-disease co. Pulmatrix appoints Robert Connelly CEO (release)

Teva acquires protein-therapeutic maker CoGenesys for $400M — CoGenesys, a Rockville, Md., protein-drug biotech spun out of Human Genome Sciences in 2006, has been acquired by Israel’s Teva Pharmaceutical Industries for $400 million in cash. The companies’ joint release is here.

CoGenesys, like its former parent HGS, is focused on the development of protein and peptide drugs for a variety of conditions. The company’s two lead drug candidates aim to treat neutropenia, a depletion of white blood cells that puts people at risk of serious infection, and heart failure.

Teva said the acquisition advances its recently revised strategic goal of pursuing biotech drugs (”biopharmaceuticals”) and generic biologics (”biogenerics”). It’s not entirely clear whether Teva is interested in pursuing CoGenesys’ actual drug pipeline or simply putting its manufacturing technology to use in Teva’s existing international biogenerics business. No biogenerics have been approved for use in the U.S.

ViewRay takes in $25M for MRI radiation-therapy guidance — Gainesville, Fla.-based ViewRay, a developer of MRI-based cancer-radiation systems, raised $25 million in a second funding round. Investors included OrbiMed Advisors, Fidelity Biosciences, Aisling Capital and Kearny Venture Partners.

ViewRay claims its system will be the first to offer real-time “volumetric” imaging of tumors concurrent with radiation treatment, which ostensibly allows radiation oncologists to compensate for organ movement. The funding will go for additional staff and the manufacture and validation of advanced prototypes of the system. Our previous coverage of the company is here.

NovaMed, Chinese clinical-research outfit, receives $14M — NovaMed, a Chinese startup that performs outsourced commercial and clinical-trial management for Chinese and international drug companies, raised $13.8 million in a second funding round. Investors included Fidelity Asia Ventures, its US affiliate, Fidelity Biosciences, and Atlas Venture.

Founded in 2005 by a former AstraZeneca executive and a Chinese Internet entrepreneur, NovaMed essentially acts as a middleman for companies with drugs they’d like to sell or test in China. Depending on the client, NovaMed says it will do everything from running clinical trials and shepherding drugs through the Chinese regulatory process to manufacturing, distributing and selling pharmaceuticals.

The company had previously raised roughly $6 million. NovaMed said it will use the new funding to expand its operations and also to in-license new drugs for deveopment or sale in China.

Lumidigm takes in $7M for optical-fingerprint ID systems — Lumidigm, an Albuquerque, N.M., developer of multispectral fingerprint scanners, raised $7 million in a third funding round, VentureWire reports, citing a regulatory filing. Investors included Epic Ventures led the round, joined by new investor Sun Mountain Capital and existing investors Fort Washington Capital Partners, Motorola Ventures, Draper Fisher Jurvetson New England and Intel Capital. Lumidigm’s technology aims to read fingerprint information both from the skin surface and from subsurface layers to improve accuracy and foil attempts to spoof the technology.

Medical-software co. Compressus aims to close $14M round — Compressus, a Washington, D.C., software maker whose products link hospitals and doctors to government agencies for public-health monitoring and emergency response, is looking for an additional $1.3 million to close out a $14.3 million third funding round, VentureWire reports. The company, which was founded by three lobbyists, has so far raised more than $27 million from angel investors.

Channel Medical Partners aims for $150M med-tech fund — Channel Medical Partners, a Skokie, Ill., VC firm focused on medical-device investments, aims to raise a $150 million second fund, VentureWire reports. The new fund would be more than triple the size of its $40 million initial fund, raised in 2001. Channel aims to fund 12 to 15 startups with the new cash, and will concentrate on device firms, although it is open to investing in diagnostics, drug delivery and “specialty supply” companies as well.

Featured companies: Advanced Bio-Surfaces, Ambit Biosciences, EnteroMedics, Molecular Vision, Skyline Ventures

UPDATED: Expanded items on Skyline Ventures, Ambit, and Molecular Vision, and moved EnteroMedics to a new item here.

Skyline Ventures raises $350M life-sciences fund — Skyline Ventures, a Palo Alto, Calif., VC firm, closed a $350 million fund for healthcare and life-sciences investments. The fund is Skyline’s fifth.

Skyline is unquestionably coming off a hot streak. As it notes in its release, three of its portfolio companies were acquired this year — Avidia, by Amgen; NimbleGen, by Roche; and NovaCardia, by Merck (the links point to our coverage). Four of its portfolio companies — Hansen Medical, Sirtris Pharmaceuticals, Map Pharmaceuticals and Targanta Pharmaceuticals — went public, of which two were big hits: Hansen is up 142 percent and Sirtris 70 percent. (Map is up 13 percent and Targanta is still down 7.5 percent.)

Skyline said it will continue to invest in a mix of early, mid- and later stage companies. The firm is targeting about 15 investments of about $15 million to $35 million per startup.

Cancer-drug maker Ambit Biosciences draws $49M — San Diego’s Ambit Biosciences, a biotech focused on new cancer drugs, raised $49.3 million in a fourth funding round. The company’s drugs block a class of signaling proteins called kinases, a technique that has yielded at least one major cancer drug — Gleevec, used to treat a form of leukemia.

Ambit’s leading drug candidate, a drug for a different form of leukemia, just got off the ground in April, so it will still be some time before anyone knows if its “discovery engine” for kinase inhibitors is yielding good drugs. That hasn’t deterred a number of biotech/pharma VC arms from investing in the latest round, including MedImmune Ventures, Roche Venture Fund and NovaQuest (an arm of Quintiles). Other investors include Apposite Capital, OrbiMed Advisors, Radius Ventures, Horizon Technology Finance, Perseus-Soros Biopharmaceutical Fund, Forward Ventures, Avalon Ventures, GIMV, Jov-CMDF, and Genechem.

EnteroMedics, obesity-device maker, almost halves IPO price target — This item has been expanded and moved here.

U.K.’s Molecular Vision acquired by Acrongenomics — Molecular Vision, a London developer of credit-card sized diagnostic devices, was acquired by Acrongenomics of Geneva for an undisclosed sum. Acrongenomics appears to be a grab-bag company that acquires promising life-science technologies and then brings them to market. The release is here.

Acrongenomics previously held a joint development agreement with Molecular Vision. Our previous coverage of Molecular Vision is here.

OTHER HEADLINES OF NOTE:

• Advanced Bio-Surfaces names David Lorenzi as new CEO (release)
• Novis Pharmaceuticals appoints Thomas E. Burke III as CEO (release)

Featured companies: Acceleron Pharma, Bledsoe Brace Systems, Eurobiobiz, Genoptix, Harmony Information Systems, ImmuneWorks, Pasteuria Bioscience, Renal CarePartners, Quantum Genomics, Synergy Software, Vitreo Retinal Technology

UPDATED: Expanded items on Genoptix and Acceleron Pharma.

Diagnostics biotech Genoptix prices IPO above range, raises up to $98M — Genoptix became one of the first biotechs in a long time to demonstrate some oomph with an IPO, pricing its shares above its expected range and then soaring nearly 50 percent in its first day of trading. Genoptix priced its shares at $17 apiece, above its expected range of $14 to $16, netting itself as much as $97.8 million in the process. (Actually, existing shareholders sold close to three-quarters of a million shares in the IPO, so the proceeds to Genoptix are more like $85.6 million.)

At the very least, the positive reception appears to support the notion that biotech investors are currently more interested in reliable service businesses such as Genoptix’s diagnostics work than they are in traditional biotech moon shots, since they offer lower risk even at the cost of slower growth. Perhaps there’s hope for Talecris Biotherapeutics after all.

We’ve covered the company here and here. The offering initially valued Genoptix at $265.2 million, although today’s share run-up to $25.35 now values the company at $395.5 million. Genoptix provides diagnostic services to cancer and blood-disease specialists in order to help with diagnosing and selecting appropriate treatments for various cancers.

Acceleron Pharma draws in $31M for tissue-regeneration drugs — Cambridge, Mass.-based Acceleron Pharma, a biotech focused on “regenerative” drugs that target a family of growth and development proteins, raised $31 million in a third funding round. Investors included Bessemer Venture Partners, MPM BioEquities, QVT Financial, Advanced Technology Ventures, Flagship Ventures, OrbiMed Advisors, Polaris Ventures, Sutter Hill Ventures and Venrock.

The company’s lead drug candidate, ACE-011, aims to stimulate bone regrowth in cancer patients. That drug should move into mid-stage clinical trials in the first quarter of next year. The company intends to begin early human tests of two other drugs — one designed to increase muscle mass and strength, the other an “anti-angiogenesis” cancer drug — next year.

OTHER HEADLINES OF NOTE:

• Medical-IT co. Harmony Info raises $28M, acquires Synergy Software (release)
• Vitreo Retinal Tech adds $3M to round for eye drugs (PE Hub)
• ImmuneWorks gets $300K for lung-disease drugs (release)
• Bledsoe Brace sells majority stake to Essex Woodlands (PE Hub)
• Quantum Genomics acquires Eurobiobiz (release)
• Renal CarePartners acquires two dialysis providers (VentureWire, sub req’d)
• Pasteuria Bioscience names David Duncan new CEO (release)

Featured companies: AirInSpace, Anacor Pharmaceuticals, Apollo Endosurgery, Ascension Health Partners, BG Medicine, CeraPedics, GlaxoSmithKline, Simplex Diabetic Supply, Zars Pharma

UPDATED: Last entry added at 2am PT on 10/8/07.

Anacor Pharma pulls in $22M from Glaxo, with hundreds of millions more on the line –Palo Alto, Calif.-based Anacor Pharmaceuticals, a biotech developing new anti-infective and anti-inflammatory drugs using boron chemistry, struck a wide-ranging partnership with GlaxoSmithKline worth up to $605 million. Anacor will receive a $12 million cash payment and a $10 million equity investment in exchange for Glaxo options to as many as eight drug candidates.

Anacor is also eligible for milestone payments on each product candidate, although the release is so badly worded it’s difficult to know exactly how much is really on the line. What the release says is that “Anacor is eligible to receive discovery, development, regulatory and commercial milestones ranging up to $252 million and $331 million for each product candidate.” Does that mean a total of $583 million for each candidate, somewhere between $252 million and $331 million, or something else altogether? You’ve got me. I’ve put in calls to both companies, and will update if someone clarifies this.

(UPDATE: A GSK representative finally called back, admitted that the original wording was unclear, and said that any given product candidate could yield maximum potential milestones of between $252 million and $331 million. Whew.)

Anacor is developing a new class of antibiotics, antifungal drugs and anti-inflammatories based on the novel properties of boron, an element that doesn’t feature largely in traditional pharmaceuticals. Its leading candidates target a fungal infection called onychomycosis and the autoimmune skin condition psoriasis. The company filed for a $58 million IPO in August; see our coverage here.

Simplex Diabetic Supply draws $50M for acquisitions — Brentwood, Tenn.-based Simplex Diabetic Supply (no Web site), a provider of diabetic testing supplies, raised $50 million for expansion. New Enterprise Associates provided the funding. Simplex Chairman Richard Pinson said the funding will allow the company to “accelerate and execute” its acquisition strategy. (UPDATE: See a longer take on this deal and what it says about the business strategies of nervous VCs here.)

Ascension Health Ventures launches $200M healthcare fund — Ascension Health Ventures, a St. Louis-based venture firm owned by the Catholic non-profit healthcare provider Ascension Health, launched a new $200 million fund. Ascension Health and two other Catholic health systems — Catholic Health Initiatives and Catholic Health East — provided the funding. The fund will target later-stage medical device, healthcare technology and healthcare service companies. The release is here.

Bone-graft substitutor CeraPedics pulls in $14M — The Lakewood, Colo., maker of a drug-infused putty that stimulates bone regrowth, raised $14.5 million of a $16.5 million first funding round, PE Hub reports, citing a regulatory filing. Orbimed Advisors led the round. CeraPedics makes a bone-graft substitute that relies on a peptide called P-15 that plays an important role initiating the formation of bone.

Apollo Endosurgery raises $11.5M for minimally invasive surgical devices — The Austin, Tex., developer of surgical devices designed for operations that utilize the body’s “natural orifices” raised $11.5 million in a first funding round. Among those providing the funding were PTV Sciences, H.I.G. Ventures, and individual investors. Apollo’s devices are specifically designed for surgeries that utilize the digestive tract in order to access the peritoneal cavity — a technique now being applied to obesity and early-stage cancers.

AirInSpace draws €6M for biodecontamination devices — Paris-based AirInSpace, a developer of devices that identify and neutralize airborne biological hazards, raised €6 million ($8.5 million) in a second funding round. Investors included Matignon Technologies and Oddo AM. AirInSpace makes devices that reduce airborne microbial pathogens, although I’ve read their release and Web site through a few times and I still don’t have a clue exactly how they’re supposed to do that.

AssayDepot gets $1.8M for drug-research service marketplace — San Diego’s AssayDepot, an Internet marketplace for the drug-research services industry, raised $1.8 million in a first funding round. Private investors provided the funding. The company is developing a marketplace intended to allow industry and academic researchers to contract for research services offered around the world.

Zars Pharma abandons IPO — Salt Lake City’s Zars Pharma, which reformulates pain drugs for delivery via skin patches, formally withdrew its proposed IPO, citing “market conditions.” Its SEC filing is here. The last we heard from the company was in late September, when Zars reportedly postponed an IPO that had been scheduled for that week. (See our previous coverage here, here and here.)

The Zars withdrawal doesn’t seem to herald any particular trend in the IPO market, which is still blowing hot and cold on biotech and pharma companies. For instance, MAP Pharmaceuticals, another specialty pharma that went public last Friday, has seen a nice share-price rise of more than 30% since its offering. Two more tests of the biotech IPO market are expected this week: BioHeart (which I covered here) and Targanta Therapeutics (our coverage here and here).

Diagnostics maker BG Medicine sets IPO range, aims for €50M — BG Medicine, a Waltham, Mass., maker of molecular diagnostics for heart disease and measuring drug response, now hopes to raise as much as €50 million ($70.8 million) in an IPO. BG Medicine plans to sell as many as 6.9 million shares at a price of €5.75 to €7.25 apiece. We last wrote about the company here.

Featured companies: Enobia, F-star, N Spine, Omni Life Science

Enobia splints together $38M for bone disorders — Montreal’s Enobia, a biotech focused on aiming drugs specifically at bone diseases, raised C$40.1 million ($38 million) in a second funding round. Investors included OrbiMed Advisors, CTI Life Sciences Fund, the Fonds de solidarite FTQ, Desjardins Venture Capital, Lothian Partners and T2C2/Bio 2000.

Enobia intends to deliver bone-related drugs directly to bone tissue in order to reduce both dosages and possible side effects. Its first drug candidate targets hypophosphatasia, a genetic disease in which bones fail to absorb minerals correctly because an enzyme called alkaline phosphatase is mutated and fails to work properly. The condition can cause stunted growth and weak or deformed bones, and in its most severe forms can be fatal.

Enobia’s drug is a bone-targeted form of alkaline phosphatase designed to make up for the defective form of the enzyme. The company said the new funding will allow it to take its experimental drug through mid-stage clinical trials.

Orthopedics-device maker Omni Life Science raises $5M in debt — Raynham, Mass.-based Omni Life Science, a maker of hip- and knee-replacement implants, raised $5 million of a planned $12 million convertible-note round, VentureWire reports (subscription required), citing a regulatory filing. Investors including Apex Partners provided the funding.

Omni was founded in 1998 as an orthopedics-device company, but the products it currently sells mostly appear to have originated with Apex Surgical, which Omni acquired in 2005. VentureWire notes that Apex Partners is also located in Raynham, Mass., and is not related to a Florida firm of the same name.

Antibody maker F-star gets €6M — Vienna-based F-star, a developer of “modular” synthetic antibodies for use as drugs, raised €6 million ($8.3 million) in a first funding round. Aescap Venture and Atlas Venture provided the funding.

All told, F-star has raised €10 million to date. The company uses a vast library of antibody features to engineer the large molecules in new ways, potentially yielding smaller antibody fragments that retain the functionality of their larger counterparts or adding additional features to existing antibodies. There’s more here, if you’re into antibody-structure engineering.

N Spine raises $1M for device commercialization — San Diego’s N Spine, a maker of spinal fusion and stabilization devices, raised $1 million in bridge funding, VentureWire reports. Individual investors provided the funding.

From the VentureWire story:

The new funding comes as N Spine has been building a market presence for the NFix II dynamic pedicle screw and rod system, which received 510(k) clearance from the Food and Drug Administration in February. “Our product has been used clinically for a year,” [chief technology officer Jude Paganelli] said. “And in the U.S., we have been selling since March.”

(UPDATED at 7:10pm PT: See below.)

Featured companies: NeurAxon, VytronUS, Avila Therapeutics, CardioNet, Ventana Medical Systems, CytoLogix, PlaCor

NeurAxon raises $32M for pain drugs — You have to hand it to Waltham, Mass.-based NeurAxon — the company certainly knows how to keep itself in the news. Today, it announced it has raised $32 million in a second funding round, a week after it reported a positive early-stage trial result for its experimental migraine treatment.

Investors included Delphi Ventures, OrbiMed Advisors, BDC Venture Capital, Genesys Capital Partners, H.I.G. Ventures, NeuroVentures Fund, Ventures West Capital and Lawrence Bloch, NeurAxon’s CEO.

Stealthy VytronUS gets $6.6M — Los Altos, Calif.-based VytronUS, a secretive medical-device company, raised $6.6 million in a first funding round, PE Hub reports, citing a regulatory filing. Delphi Ventures and New Enterprise Associates provided the funds.

Avila Therapeutics receives undisclosed first funding — Avila Therapeutics, a Waltham, Mass., biotech focused on cancer and viral disease, raised an undisclosed first funding round in February, VentureWire reports (subscription required). Investors included Abingworth Management, Advent Venture Partners, Atlas Venture and Polaris Venture Partners. The company doesn’t have a Web site.

Wireless heart monitor CardioNet files to raise $150M in an IPO — CardioNet, a San Diego medical-device firm focused on wireless heartbeat monitors, filed to raise up to $150 million in an IPO. The company still isn’t profitable, although its sales appear to be set to double this year.

The In Vivo blog has some additional insight into CardioNet’s rather convoluted funding history.

Defunct device maker wins patent case against Ventana — CytoLogix, a failed medical-device startup formerly based in Cambridge, Mass., won a patent-infringement suit against publicly traded Ventana Medical Systems of Tuscon, Ariz. A jury awarded CytoLogix $10.8 million in damages, but said Ventana wasn’t liable for related antitrust claims. CytoLogix attorneys have said they will seek to have the damages paid to the company’s shareholders, VentureWire reports.

From VentureWire:

CytoLogix alleged in the patent litigation that Ventana learned about CytoLogix’s proprietary intellectual property by gaining access to a confidential business plan that CytoLogix had distributed in the mid-1990s as part of its search for venture capital. This allegation stemmed from an admission made by Ventana’s then-Chairman Jack Schuler, as part of an address he made in October 1999, at a U.S. Trust investment conference in Tarrytown, N.Y.

In the speech, Schuler described in detail how years before, Ventana had made use of information in the business plan. A 2002 Barron’s article about the litigation quotes him in the speech as having acknowledged the competition in a major way.

CytoLogix sold its business operations to Dako in 2002, and currently exists only to pursue the litigation. Ventana, meanwhile, is trying to fend off an unsolicited takeover offer from Roche.

The original Barron’s article on the lawsuit is here, and there’s a little more detail on the decision in this AP story.

PlaCor names new CEO — PlaCor, a Plymouth, Minn., developer of blood-cell diagnostics, named John Reinke as CEO, effective Sept. 4. PlaCor is developing diagnostic tests of platelet reactivity intended to determine patient response to anticoagulant treatment following serious blood-clot incidents, which can lead to heart attacks or strokes. Current CEO Bill Haworth will become the company’s chief scientific officer.

UPDATE (7:10pm PT): Added items on Ventana/CytoLogix lawsuit and PlaCor.

Athersys, a Cleveland, Ohio biotech, went public via reverse merger and raised $65 million in a private placement. The company’s release is here.

Founded in 1995, Athersys is active in a bewildering number of areas. Its lead product candidate is an appetite-suppressing drug that acts on a serotonin receptor in the brain called 5HT2c, and in general the company describes itself as focused on metabolic and neurological conditions. But it is also at work on an adult-derived stem-cell treatment for heart disease, stroke and bone-marrow transplant patients. None of these products, however, appear to be in human trials yet, which is sort of intriguing given how long the company has been around.

It turns out that Athersys is also a biotech chameleon. In 2000, it filed to raise $115 million in an IPO. According to its S-1 registration statement, the company was then a “functional genomics” company, which essentially means it surveyed large numbers of genes in an attempt to determine their function. Although popular during the genomics bubble of 1999-2000, this sort of business tended not to pan out for many companies. Athersys withdrew its proposed IPO six months after it was filed.

The Athersys funding was led by Radius Ventures, joined by OrbiMed Advisors, RA Capital Management, Accipiter Capital Management, Hambrecht & Quist Capital Management, MPM BioEquities, and Pappas Ventures.

Hayward, Calif.-based Singulex, a developer of sensitive molecular-detection systems, raised $19 million in a fourth funding round. The company’s release is here.

The company is developing an analysis system, called Erenna, plus related “assays,” or specially designed biochemical tests, that are designed to detect individual protein molecules in biological samples such as blood. Such tests could be useful for detecting or diagnosing disease, monitoring the effect of drug treatment, and other research and diagnostic purposes. For instance, Singulex says its system can identify previously undetectable cellular levels of cardiac troponin I, a protein biomarker that can be used to measure tissue damage following a heart attack. The company claims that its system can actually count the number of proteins in a given sample.

Singulex already offers its services to research centers at biotech and pharmaceutical companies, and hopes also to break into the field of molecular diagnostics — a much more challenging and heavily regulated area.

The round was led by OrbiMed Advisors, joined by existing investors Fisk Ventures (a venture fund of H. Fisk Johnson, CEO of S.C. Johnson & Son), Prolog Ventures, and Advantage Capital. Singulex has raised $31.6 million to date, according to VentureWire (subscription required).